Another clinical trial using a competitive inhibitor of the binding between uPA and uPAR, called A6, showed minimal beneficial effects on patients with gynecological tumors such as the ovary, fallopian tube, and peritoneum (36). Here, PLAU is linked to female reproductive system neoplasm.